Value through Innovation27 July 2016

Clinical Study Results

  • Talsaclidine - Alzheimer Disease
    Clinical Study Number 506.203
    Study Indication Alzheimer Disease
    Product Talsaclidine
    Generic Name Talsaclidine
    Lab Code
    Clinical Phase IIb
    Study Title

    Efficacy and safety of 6, 12, 24, and 36 mg tid po and 36 mg bid potalsaclidine (free base) for 12 weeks in a double-blind, randomised, placebo-controlled parallel group comparison in patients with mild to moderate dementia of Alzheimer type

    Study Document Trial synopsis 506.203_CO english
  • Talsaclidine - Alzheimer Disease
    Clinical Study Number 506.208
    Study Indication Alzheimer Disease
    Product Talsaclidine
    Generic Name Talsaclidine
    Lab Code
    Clinical Phase IIb/III
    Study Title

    An open-label multicentre, follow-up trial to assess the long-term safety and tolerability of oral administration of talsaclidine 24mg tid in patients with mild to moderate dementia of the Alzheimer type

    Study Document Trial synopsis 506.208 english
  • Talsaclidine - Alzheimer Disease
    Clinical Study Number 506.209
    Study Indication Alzheimer Disease
    Product Talsaclidine
    Generic Name Talsaclidine
    Lab Code
    Clinical Phase IIb
    Study Title

    Efficacy and safety of 48 mg talsaclidine (free base) tid po (Panel1) and 60mg talsaclidine (free base) tid po (Panel2) for 12 weeks in a double­blind, randomised, placebo-controlled within escalating dose panels in 150 patients with mild to moderate dementia of Alzheimer type

    Study Document Trial synopsis 506.209_CO english
  • BI 409306 - Alzheimer Disease
    Clinical Study Number 1289.7
    Study Indication Alzheimer Disease
    Product BI 409306
    Generic Name BI 409306
    Lab Code BI 409306
    Clinical Phase II
    Study Title

    A multi-centre, double-blind, parallel-group, randomised controlled study to investigate efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared to placebo in patients with cognitive impairment due to Alzheimer’s Disease

    Study Document Trial synopsis 1289.7 english Lay summary 1289.7 english
  • BI 409306 - Alzheimer Disease
    Clinical Study Number 1289.5
    Study Indication Alzheimer Disease
    Product BI 409306
    Generic Name BI 409306
    Lab Code BI 409306
    Clinical Phase II
    Study Title

    A multi-centre, double-blind, parallel-group, randomized controlled study to investigate the efficacy, safety and tolerability of orally administered BI 409306 during a 12-week treatment period compared to placebo in patients with Alzheimer’s Disease

    Study Document Trial synopsis 1289.5 english Lay summary 1289.5 english

Clinical Trial Registry and structured study results. Find here protocol information for all clinical study types.

European Trial Register of EU studies.